on Relief Therapeutics Holding SA (ETR:RLF)
MindMaze Therapeutics Releases 2025 Annual Report and Strategic Update
MindMaze Therapeutics has announced the release of its 2025 Annual Report, focusing on key advancements in its neurotherapeutics platform. The Geneva-based company made significant strides in U.S. market expansion and reimbursement strategy, as evidenced by a collaboration with Vibra Healthcare and statistically significant improvements in patient outcomes.
The report highlights the commercial rollout of MindMaze's platform across various care settings. Appointing Zach Henderson as CEO, the company integrates clinical foundations with business strategies. A business combination with NeuroX marks a milestone, resulting in the realignment of MindMaze's operations toward precision neurotherapeutics.
Financially, MindMaze reported CHF 0.6 million in revenue against CHF 9.9 million net loss, reflecting investment in technology and commercial initiatives. For 2026, MindMaze aims to scale its U.S. operations, broaden application outlets, and establish significant partnerships to promote its platform further.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Relief Therapeutics Holding SA news